US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Presentation of Updated MATINS Data at ESMO

Faron Pharmaceuticals Ltd. (“Faron”) Faron Announces Presentation of Updated MATINS Data at ESMO Showing Bexmarilimab Delivers Compelling Antitumour Activity Across Five Different Advanced Solid Tumors   ·Strongest disease control rate (DCR) observed in five different tumor types – cutaneous melanoma (30%), gastric cancer (30%), cholangiocarcinoma (30%), hepatocellular carcinoma (40%) and breast cancer (40%) patients · Landmark analysis estimates overall survival at six months for DCR (partial response + stable disease rate) patients at 83% compared to 29% for non-DCR

Presentations at ESMO Immuno-Oncology Virtual Congress build case for CLEVER-1 as a new immune checkpoint target

Data from ongoing PhI/II MATINS trial showcasedRole of myeloid cells in shaping the tumour microenvironment highlightedCompany announcement, 10 December 2020 at 9.00 AM (EET)TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that two presentations at the European Society of Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 will showcase data from the Company’s PhI/II MATINS study and explore the role of myeloid cells in shaping the tumour microenvironment (TME). ‘CLEVER-1 a new immune

MATINS trial data presented at ESMO

Data from completed Part I of bexmarilimab MATINS trial presented at ESMO Virtual Congress 2020TURKU – FINLAND, 18 September 2020 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, today announces details from an oral presentation being held at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, showcasing data from the Company’s ongoing MATINS trial to the scientific community. The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of bexmarilimab, Faron's wholly-owned novel

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe